Zuari Agro Chemicals Receives Four MCA Interim Orders Over Alleged Accounting Non-Compliances
Zuari Agro Chemicals disclosed four interim orders from the MCA's Regional Director, Western Region, Mumbai, dated 8th May 2026, related to compounding applications for alleged non-compliances under Section 129 of the Companies Act, 2013. The violations span accounting disclosure and presentation matters under IND AS-33, IND AS-36, IND AS-37, and Schedule III across FY 2019-20 to FY 2022-23. While the company faces no material financial or operational impact and was not levied any compounding fees, a total of Rs. 66.00 lakhs was collectively imposed on the Executive Director, Promoter directors, Director, CFO, Ex-Director, and Ex-CFO.

*this image is generated using AI for illustrative purposes only.
Zuari Agro Chemicals has disclosed the receipt of four interim orders from the Regional Director, Western Region, Ministry of Corporate Affairs (MCA), Mumbai, dated 8th May 2026. The disclosure was made pursuant to Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The orders relate to compounding applications filed under Section 441 of the Companies Act, 2013 for alleged non-compliances under Section 129 of the Companies Act, 2013.
Nature of Interim Orders
The four interim orders were passed by the Regional Director, Western Region, Mumbai, in connection with compounding applications submitted by the company's Executive Director, Promoter directors, Director, and Key Managerial Personnel (KMPs), including earlier directors and KMPs. The alleged non-compliances pertain to accounting disclosures and presentation matters, which the company characterised as unintentional and procedural in nature. The orders involve alleged violations under IND AS-33, IND AS-36, IND AS-37, and Schedule III of the Companies Act, 2013.
Details of Alleged Violations
The following table summarises the specific alleged violations cited in the interim orders:
| Particulars: | Details |
|---|---|
| IND AS-33 | Non-disclosure/presentation of Basic and Diluted EPS separately for FY 2019-20 to FY 2022-23 |
| IND AS-36 | Alleged non-compliance relating to impairment assessment of investment in Zuari Farmhub Limited for FY 2019-20 to FY 2022-23 |
| IND AS-37 | Alleged non-compliance relating to deferred tax assets and related disclosures for FY 2020-21 and FY 2021-22 |
| Schedule III | Disclosure-related non-compliance relating to separate disclosure of legal and professional expenses for FY 2020-21 and FY 2021-22 |
Financial and Operational Impact
Zuari Agro Chemicals stated that the interim orders have no material impact on the financials, operations, or other activities of the company. The company itself was not levied with any compounding fees pursuant to the said orders. However, pursuant to the four interim compounding orders, a total compounding fee amounting to Rs. 66.00 lakhs was levied collectively on the Executive Director, Promoter directors, Director, CFO, Ex-Director, and Ex-CFO.
Regulatory Disclosure
The intimation was signed by Asheeba Pereira, Company Secretary, on 9th May 2026, and submitted to both BSE Limited and the National Stock Exchange of India Ltd. The company requested both exchanges to take the information on record. The disclosure was made in compliance with applicable SEBI LODR requirements governing timely intimation of orders and directions received from regulatory authorities.
Historical Stock Returns for Zuari Agro Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.04% | +3.88% | -10.80% | -18.85% | +4.03% | +125.57% |
Will the compounding fee levied on Zuari Agro Chemicals' directors and KMPs trigger any leadership changes or affect the company's corporate governance framework going forward?
Could the MCA's scrutiny of Zuari Agro Chemicals' accounting disclosures prompt a broader regulatory review of IND AS compliance practices across the Indian agrochemical sector?
How might repeated disclosure-related non-compliances influence institutional investor confidence and the company's ability to raise capital in future fundraising activities?


































